Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 23;4:57. doi: 10.1038/s41421-018-0058-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — At study termination on July 2015 in the first discovery stage, 2615 patients with HF had been screened for eligibility to be included in the study in three centers in China and 2403 patients were finally enrolled and genotyped. Of these patients, 149 (5.7%) were excluded for repeat admittance, and 63 (2.4%) were excluded because valvular heart disease was considered the main reason for HF. Of the study participants, 17 were lost from follow-up because incorrect contact information had been provided on enrollment. Of the 2386 patients included in the outcome analysis: all were included in the analysis of the prognostic utility of the ADRB2 Arg16Gly, ADRB2 Gln27Glu, and GRK5 Arg304His variants; 2377 patients were included in the analysis of the prognostic utility of the ADRB1 Arg389Gly variants; and 2384 patients were included in the analysis of the prognostic utility of the GRK5 Gln41Leu variants